The FDA's big gamble on the new Alzheimer's drug
- Written by C. Michael White, Distinguished Professor and Head of the Department of Pharmacy Practice, University of Connecticut

The Food and Drug Administration set off a firestorm of debate when it approved a new drug, aducanumab, for Alzheimer’s disease via an accelerated approval pathway. This decision ignored the...